• A
  • A
  • A

Ute Moll, MD, MS

Vice Chair for Experimental Pathology
Basic Sciences Tower, Level 9
Stony Brook Medicine
Stony Brook, NY 11794-8691

Tel: (631) 444-2459
Fax: (631) 444-3424
Email: Ute.Moll@stonybrookmedicine.edu

Clinical Practice:

Dr. Moll currently participates in the autopsy program at Stony Brook University Hospital.

Institution & LocationDegreeYear(s) Field of Study
University of Ulm, GermanyMS1980Biology
University of Ulm, GermanyMD1985Medicine

Positions and Employment:

1986-1989Resident, Anatomic & Clinical Pathology, Stony Brook University
1989-1990Postdoctoral Research Fellow, Stony Brook University, lab of Dr. James Quigley
1991-1992Postdoctoral Research Fellow, Princeton University, lab of Dr. Arnold J. Levine
1992-1997Assistant Professor, Department of Pathology, Stony Brook University
1997-2001Associate Professor, Department of Pathology, Stony Brook University
2002-presentFull Professor, Department of Pathology, Stony Brook University
2009-presentVice Chair, Research, Department of Pathology Stony Brook University
2012-presentCo-Director, Stem Cell Analysis Core, Stony Brook Stem Cell Facility

Other Experience and Professional Memberships (selected):

1988-1989Chief Resident, Department of Pathology, Stony Brook University
2007-presentGuest Professor, Department of Molecular Oncology, University of Göttingen, Germany

Honors (selected):

2006Baldwin Award for Cancer Research, Stony Brook University
2011Baldwin Award for Cancer Research, Stony Brook University
2012Fusion Award, Stony Brook University
2013Inaugural Excellence in Basic Research Award, School of Medicine, Stony Brook University

Peer Reviewed Publications (selected):

1. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM (2002). DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in human tumors. J Exp Med 196(6): 765-80.

2. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM (2003). p53 has a direct apoptogenic role at the mitochondria. Mol CELL 11(3): 577-90.

3. Petrenko O and Moll UM (2005). Macrophage Migration Inhibitory Factor MIF Interferes with the Rb-E2F Pathway. Mol CELL 17(2): 225-36.

4. Talos F, Petrenko O, Mena P and Moll UM (2005). Mitochondrially Targeted p53 has Tumor Suppressor Activities In vivo. Cancer Res 65(21):1-11.

5. Marchenko ND, Wolff S, Erster S and Moll UM (2007). Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 26(4):923-34.

6. Flaminia Talos, Alice Nemajerova, Elsa R. Flores, Oleksi Petrenko and Moll UM (2007). p73 maintains the integrity of the genome and prevents rereplication. Mol CELL 27(4): 647-59.

7. Wolff S, Talos F, Palacios G, Beyer U, Dobbelstein M, Moll UM (2009). The alpha/beta carboxyterminal domains of p63 are required for skin and limb development. Cell Death & Diff 16(8): 1108-17.

8. Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, Bode D, Dobbelstein M, Brück W, Moll UM (2010). p73 is an essential regulator of neural stemcell maintenance in embryonal and adult CNS neurogenesis. Cell Death & Diff 17(12):1816-29.

9. Nemajerova A, Petrenko O, Trümper L, Palacios G, Moll UM (2010). Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. J Clin Invest 120(6):2070-80.
Click here to view article.

10. Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M (2011). Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. PNAS  108(9):3624-9.
Click here to view rearch highlights.

11. Li D, Marchenko, ND Fischer V, Velasco-Hernandez T, Talos F, Moll UM (2011). Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Canc Res 9(5):577-88.
Click here to view article.

12. Li D, Marchenko ND and Moll UM (2011). SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death & Diff 18(12):1904-1913.
Click here to view article.

13. Schulz R, Marchenko ND, Holembowski, Dobbelstein M, Moll UM (2012). Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression J Exp Med 209(2):275-289.
Click here to view article.

14. Nemajerova A, Kim SY, Petrenko O, Moll UM. Two-factor reprogramming of somatic cells to pluripotent stem cells reveals partial functional redundancy of Sox2 and Klf4. Cell Death Differ. 2012 Aug;19(8):1268-76. doi: 10.1038/cdd.2012.45. Epub 2012 Apr 27. PubMed PMID: 22539002; PubMed Central PMCID: PMC3392633.
Click here to view article.
Click here to view editorial.

15. Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem. 2012 Feb;113(2):433-9. doi: 10.1002/jcb.23400. Review.
Click here to view article.

16. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012). p53 opens the mitochondrial permeability transition pore to trigger necrosis. CELL 149, 1536-1548.
Click here to view brief research highlights.
Click here to view more research highlights.
Click here to view article.

17. Alexandrova EM, Talos F, Moll UM. p73 is dispensable for commitment to neural stem cell fate, but is essential for neural stem cell maintenance and for blocking premature differentiation. Cell Death Differ. 2012 Oct 26. doi: 10.1038/cdd.2012.134. [Epub ahead of print] PubMed PMID: 23099852.

18. Sorrentino G, Mioni M, Giorgi C, Ruggeri N, Pinton P, Moll U, Mantovani F, Del Sal G (2012). The prolyl-isomerase Pin1 activates the mitochondrial death program of p53. Cell Death Differ. 2012 Aug 31. doi: 10.1038/cdd.2012.112.

19. Ischenko I, Zhi J, Nemajerova A, Moll UM, Petrenko O. Direct Reprogramming by oncogenic Ras and Myc. PNAS, 2013, 110(10):3937-42.
Click to view article.

20. Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll UM (2012) Two hotspot mutant p53 mouse models display differential gain-of-function in tumorigenesis. Cell Death Differ Mar 29. doi: 10.1038/cdd.2013.17.
Click to view article.
Click to view editorial.